Logo 1 Logo 2

Clinical Trial Details

Trial ID: L1825
Source ID: NCT04893148
Associated Drug: Iglarlixi
Title: Efficacy and Safety of iGlarLixi Versus Insulin Glargine Plus Dulaglutide in Patients With Type 2 Diabetes
Acronym:
Status: UNKNOWN
Study Results: NO
Results:
Conditions: Type 2 Diabetes Mellitus|Glucose, High Blood
Interventions: DRUG: IGlarLixi|DRUG: Dulaglutide
Outcome Measures: Primary: Changes in glycated hemoglobin (HbA1c), HbA1c will be measured at baseline and week 12, Baseline, week 12 | Secondary: Changes in fasting plasma glucose (FPG), Comparison of FPG changes in week 12 from baseline between the two groups, Baseline, week 12|Changes in glucose time in range (TIR), Comparison of %TIR changes in week 12 from baseline between the two groups, Baseline, week 12|Changes in glucose time above range (TAR), Comparison of %TAR changes in week 12 from baseline between the two groups, Baseline, week 12|Changes in glucose time below range (TBR), Comparison of %TBR changes in week 12 from baseline between the two groups, Baseline, week 12|Incidence of hypoglycemia, Comparison of the incidence of hypoglycemia between the two groups, Baseline, week 12|Changes in weight, Comparison of weight changes in week 12 from baseline between the two, Baseline, week 12
Sponsor/Collaborators: Sponsor: Chungbuk National University Hospital
Gender: ALL
Age: ADULT, OLDER_ADULT
Phases: PHASE4
Enrollment: 40
Study Type: INTERVENTIONAL
Study Designs: Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT
Start Date: 2020-05-26
Completion Date: 2022-12-30
Results First Posted:
Last Update Posted: 2022-07-20
Locations: Chungbuk National University Hospital, Cheonju, Chungcheongbuk-do, 28644, Korea, Republic of
URL: https://clinicaltrials.gov/show/NCT04893148